← Back to Search

Antiplatelet Agent

MK-2060 for Kidney Failure

Phase 1

Waitlist Available

Research Sponsored by Merck Sharp & Dohme LLC

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 168 hours post-dose

Awards & highlights

Study Summary

This trial is testing a new drug, MK-2060, to see if it is safe and effective in preventing blood clots in people with kidney failure.

Eligible Conditions

Kidney Failure
Chronic Kidney Failure

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 168 hours post-dose

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~168 hours post-dose

This trial's timeline: 3 weeks for screening, Varies for treatment, and 168 hours post-dose for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Number of Participants who Discontinue Study Intervention Due to an AE

Number of Participants who Experience One or More AEs

Number of Participants who Experience One or More Bleeding Related Adverse Events (AE)

Secondary outcome measures

Area Under the Concentration-Time Curve from 0 to 168 Hours (AUC0-168) of MK-2060

Clearance (CL) of MK-2060

Maximum plasma concentration (Cmax) of MK-2060

+5 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: MK-2060Experimental Treatment1 Intervention

MK-2060 administered via intravenous (IV) infusion on days 1, 3, and 5 during the first week and on day 8 during the second week.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

MK-2060

2019

Completed Phase 1

~70

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Merck Sharp & Dohme LLCLead Sponsor

3,890 Previous Clinical Trials

5,060,289 Total Patients Enrolled

1 Trials studying Kidney Failure

8 Patients Enrolled for Kidney Failure

Medical DirectorStudy DirectorMerck Sharpe & Dohme LLC

2,777 Previous Clinical Trials

8,063,728 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the ultimate objectives of this research endeavor?

"The primary aim of this 104-day medical trial is to assess the occurrence of haemorrhaging-related adverse events amongst participants. Additionally, researchers will be measuring plasma concentration at 168 hours post dose (C168), area under the curve from 0 to 168 hours (AUC0-168) and time until maximum plasma concentration (Tmax)."

Answered by AI

Is the eligibility criterion of this trial restricted to individuals over 40 years old?

"The age range for participants in this research is between 18 and 80."

Answered by AI

Is this research initiative currently looking for participants?

"Per the data hosted on clinicaltrials.gov, this investigation is not presently seeking participants. The trial was initially posted in May of 2022 and last edited almost six months later; however, there are currently 676 other trials that accept new members."

Answered by AI

Has the FDA given clearance to MK-2060?

"MK-2060's safety is only backed by limited data, so it has been ranked a 1 on the safety scale."

Answered by AI

Who qualifies to participate in this clinical experimentation?

"To be eligible for this medical experiment, volunteers must have chronic renal failure and be between 18 to 80 years old. A total of 12 people are needed for the research endeavour."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

MK-2060 and Clopidogrel Co-administration Safety and Tolerability Study in Participants With End-Stage Renal Disease (ESRD) (MK-2060-008)

2022. "MK-2060 and Clopidogrel Co-administration Safety and Tolerability Study in Participants With End-Stage Renal Disease (ESRD) (MK-2060-008)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05335005.